



SCOTTISH HEALTH PROTECTION NETWORK
Promoting and Supporting Good Practice



External Guidance Addendum

This guidance has been approved for use in Scotland by the Scottish Health Protection Network Guidance Group (SHPN-GG). The guidance should be used in conjunction with the addendum outlined below.

Guidance name:	Guidance for the laboratory investigation, management and infection prevention and control for cases of <i>Candida auris</i> , PHE, 2017
Name of sponsor SHPN-Topic/ Coordination Group:	SHPN Public Health Microbiology Group
Name of individual/s providing addendum information:	Michael Lockhart
Date of guidance sign-off by SHPN-GG:	20/12/2017
Addendum required:	<p>Guidance users- please note the following advice with respect to using the PHE guidance in Scotland. This addendum will be reviewed and updated as necessary, in light of any emerging epidemiological updates.</p> <p><u>Investigation in Clinical Laboratories (page 4)</u></p> <p>The following supplementary information relates to the need for identification to species level for:</p> <ul style="list-style-type: none"> • Any <i>Candida</i> spp. isolates from blood cultures • As a minimum, other isolates judged as clinically significant from deep sample sites from all patients • Any isolates from patients transferred from an affected hospital (UK or abroad) <p>At the moment Bruker MALDI-TOF (Biotyper) is the most reliable speciation system for <i>C. auris</i>. For laboratories which do not have this system we suggest that any isolate that identifies as <i>C. famata</i>, <i>C. haemulonii</i>, <i>C. sake</i>, <i>C. lusitaniae</i>, <i>Saccharomyces cerevisiae</i>, or unidentified isolates, is screened for ability to grow at 42°C and/or high level fluconazole resistance by disc, antimicrobial gradient diffusion method (e.g. Etest) or VITEK 2, or is sent to a laboratory with a Bruker MALDI-TOF Biotyper for confirmation.</p> <p>Suspicious/possible <i>C. auris</i> isolates should be sent to the PHE Mycology</p>

	<p>Reference laboratory in Bristol.</p> <p>The fluconazole disc method reference is: CLSI M44 A2 (Clinical and Laboratory Standards Institute. 2009. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts, 2nd ed. Approved Guideline. Document M44-A2. Clinical and Laboratory Standards Institute, Wayne, PA.) For Vitek 2 and Gradient diffusion as per manufacturers guidance.</p> <p><u>Infection, prevention and control (IPC) (page 10)</u></p> <p>Please refer to the National Infection Prevention and Control Manual (NIPCM) http://www.nipcm.hps.scot.nhs.uk</p>
--	---